Michael Nauck is Head of Clinical Research at the Diabetes, Endocrinology and Metabolism Section, Medical Department 1, St. Josef-Hospital and teaches at the Ruhr-University Bochum in Bochum, Germany. He was trained in gastroenterology and endocrinology with Werner Creutzfeldt and since has had a particular research interest in the role of gastrointestinal peptide hormones (incretins: GIP and GLP-1) in the physiological regulation of metabolism and in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a definite therapeutic potential of GLP-1 in patients with type 2 diabetes. Since, he has been involved in the development of incretin-based glucose-lowering medications such as GLP-1 receptor agonists and, more recently, co-agonists able to stimulate other receptors besides the GLP-1 receptor (e.g., tirzepatide), and inhibitors of dipeptidyl peptidase-4. Additional areas of interest include diagnostic challenges regarding insulinomas, cardiovascular complications of type 2 diabetes, and the modification this risk in type 2-diabetic patients by using beneficial glucose-lowering pharmacotherapy. Michael Nauck was a member of the writing group preparing the 2012 and 2015 “Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) on the management of hyperglycaemia in type 2 diabetes”.

Michael Nauck’s scientific contributions have been honoured with several awards, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the German Diabetes Association, and the Claude Bernard Medal of the European Association for the Study of Diabetes. In 2017, he was appointed Doctor honoris causa by the University of Copenhagen, Denmark.

Michael Nauck is member of the German, European, and American Diabetes Associations, and of the International Diabetes Federation. He has served as reviewer for all major diabetes journals and has published more than 250 original articles and 150 reviews or book chapters. His publications have been quoted > 66,000 times, his “H-index” is 108, and he has been identified as a “highly-cited researcher” (among the top 1%) in recent years (Web of Knowledge).